Cover Image
市場調查報告書

新興市場上醫療市場進入:HTA (醫療技術評估)

Access in Emerging Markets: HTA is Making Inroads

出版商 Datamonitor Healthcare 商品編碼 342051
出版日期 內容資訊 英文 119 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
新興市場上醫療市場進入:HTA (醫療技術評估) Access in Emerging Markets: HTA is Making Inroads
出版日期: 2015年04月16日 內容資訊: 英文 119 Pages
簡介

面對嚴苛的競爭環境及成長率低落,許多製藥企業視新興市場為收益成長之源。新興國家正在以擴大醫療保險範圍及投資醫療制度來改善醫療服務網,但由於資源有限,必須發現調整需求的方法。結果政府與政策籌劃者開始活用HTA (醫療技術評估),這個新動向將會改變市場進入環境及製藥公司及主要相關利益者的參與方法。

本報告涵括新興市場上改善進入醫療市場所用的HTA (醫療技術評估) ,提供您HTA利用的促進要素·阻礙要素,HTA的多元化實施方法,HTA和相關利益者的關聯,及各國的HTA趨勢等分析。

摘要整理

HTA利用的促進要素·阻礙要素

  • 醫療成長的抑制促進了HTA的需求
  • 對有效的HTA利用而言還仍有許多障礙
  • HTA的利用帶來了困難的市場進入條件
  • 參考文獻

用各種方法所實行的HTA

  • 依國家需求·愛好不同而以不同方法引進·實施HTA
  • 國際合作形成了HTA的發展,建立新興市場上功能,不過仍留下了多樣性
  • 參考文獻

製藥公司的HEOR (醫療組織) 的投資擴大

  • 公共市場區隔的醫藥品銷售額擴大必須改變策略
  • 製藥公司HEOR的投資在新興市場中擴大,但ROI的最大化需要實用的方法
  • 參考文獻

HTA和相關利益者有關

  • 正式的HTA建議流通管道以技術面為焦點
  • 相關利益者與政策籌劃者的非正式關係已屬當然
  • 官民聯盟展現出政府和供應商的廣泛關係上的機會
  • 參考文獻

巴西

中國

墨西哥

波蘭

韓國

台灣

目錄
Product Code: DMKC0138547

Faced with tough competitive conditions and declining growth rates, many pharma companies are looking towards emerging markets as sources of revenue growth. Growing economies and a burgeoning middle class, as well as expanding healthcare systems, have resulted in high growth rates and increased demand for Western medicines.

However, as developing countries strive to improve access to healthcare by expanding insurance coverage and investing in healthcare system infrastructure, growing patient expectations are increasingly forcing them to find a way of reconciling demand with limited resources. Consequently, governments and policymakers have begun to utilize health technology assessment to this end, and this new trend has changed the market access landscape and the way in which pharma interacts with key stakeholders.

This report addresses the following questions:

  • How is HTA use impacting access in emerging markets?
  • What are the differences between HTA use in different emerging market countries?
  • How have pharma's strategies adapted in reaction to the changes brought about by HTA?
  • What channels exist for pharma-HTA engagement?
  • What are the key lessons for success in overcoming hurdles presented by HTA in emerging markets?

TABLE OF CONTENTS

EXECUTIVE SUMMARY

DRIVERS AND RESISTORS OF HTA USE

  • 1. Healthcare growth containment drives need for HTA
  • 2. A number of obstacles remain to effective HTA use
  • 3. More challenging market access conditions are resulting from HTA use
  • 4. Bibliography

HTA IS IMPLEMENTED IN A VARIETY OF WAYS

  • 5. HTA is adopted and implemented in a variety of ways depending on a country's needs and Preferences
  • 6. International collaboration is shaping HTA development and capacity building in emerging markets, but variations will remain
  • 7. Bibliography
  • PHARMA'S INVESTMENT IN HEOR IS GROWING
  • 8. Growing pharma sales in the public segment necessitate shift in strategy
  • 9. Pharma's investment in HEOR in emerging markets is growing, but a pragmatic approach is critical to maximize ROI
  • 10. Bibliography

HTA AND STAKEHOLDER ENGAGEMENT

  • 11. Formal HTA advice channels focus on technical aspects
  • 12. Informal engagement of stakeholders and policy makers is commonplace
  • 13. Public-private partnerships present an opportunity for wider engagement with governments and providers
  • 14. Bibliography

BRAZIL

  • 15. Brazil has established itself as a leader in HTA in Latin America
  • 16. Universal healthcare coverage necessitated introduction of a formal HTA process
  • 17. Establishment of CONITEC represents a major step in strengthening HTA process in Brazil
  • 18. Communication with CONITEC focuses on the technical checking of the dossiers, but the agency is open to further engagement
  • 19. Threat of spill-over effect into private insurance coverage enhances importance of CONITEC approval
  • 20. Bibliography

CHINA

  • 21. China lags behind in its capacity to use HTA, but slow change is set to occur
  • 22. Universal health insurance coverage as a result of healthcare reforms
  • 23. Bibliography

MEXICO

  • 24. HTA in Mexico lags behind Brazil
  • 25. The Mexican health insurance system is fragmented
  • 26. The CSG is the key HTA body in Mexico and decides on national reimbursement
  • 27. Bibliography

POLAND

  • 28. Poland is a leader in HTA in Central and Eastern Europe
  • 29. Public health insurance provides coverage to 98% of the Polish people
  • 30. Bibliography

SOUTH KOREA

  • 31. South Korea's HIRA has emerged as the leader in HTA in the Asia Pacific region
  • 32. South Korea's health insurance system is based on a single major payer
  • 33. HIRA and NECA are the key HTA bodies in South Korea
  • 34. Bibliography

TAIWAN

  • 35. Taiwan has introduced HTA, but has limited capacity to carry out full assessment
  • 36. The Taiwanese healthcare system has a single payer
  • 37. The pricing and reimbursement process was reformed in 2013
  • 38. Bibliography
Back to Top